Children as young as three will start receiving Covid-19 vaccines in China amid a rise in outbreaks across several provinces.
Local city and provincial governments in at least five provinces issued notices in recent days announcing that children aged three to 11 will be required to get their vaccinations.
76 percent of China’s population has been fully vaccinated as authorities look to uphold a zero-tolerance policy towards outbreaks.
The expansion of the vaccination campaign comes as parts of China take new clampdown measures to try to stamp out small outbreaks.
Children as young as three will start receiving Covid-19 vaccines in China amid a rise in outbreaks across several provinces (pictured: a queue outside a vaccination hub in Beijing)
Children as young as three will start receiving Covid-19 vaccines in China amid a rise in outbreaks across several provinces (pictured: a school pupil in Shanghai receives a vaccine)
China’s government has taken a no-tolerance policy towards the spread of infections and has not hesitated to introduce immediate lockdowns as well as major vaccine drives. The call for three-year-olds to be vaccinated comes amid another rise in cases
China has employed lockdowns, quarantines and compulsory testing for the virus throughout the pandemic and has largely stamped out cases of local infection while fully vaccinating 1.07 billion people in its population of 1.4 billion.
In particular, the government is concerned about the spread of the more contagious Delta variant by travellers and is committed to having a largely vaccinated public ahead of the Beijing Winter Olympics in February.
Overseas spectators have already been banned from the Games, and participants will have to stay in a bubble separating them from people outside.
it comes as Gansu, a north-western province heavily dependent on tourism, closed all tourist sites on Monday after finding new Covid-19 cases, while residents in parts of Inner Mongolia have been ordered to stay indoors due to an outbreak there.
The National Health Commission reported 35 new cases of local transmission had been detected over the past 24 hours, four of them in Gansu.
China’s most widely used vaccines, from Sinopharm and Sinovac, have shown efficacy in preventing severe disease and transmission of the virus, based on public data.
But the protection they offer against the Delta variant has not been answered definitively, although officials say they remain protective.
Hubei, Fujian and Hainan provinces all issued provincial level notices alerting new vaccination requirements, while individual cities in Zhejiang province and Hunan province have also issued similar announcements.
China in June had approved two vaccines – Sinopharm’s from the Beijing Institute of Biological Products and Sinovac – for children aged three to 17, but it has only been vaccinating those aged 12 and older.
In August, regulators approved another, Sinopharm’s from the Wuhan Institute of Biological Products.
After the vaccines received domestic approval for children in China, foreign governments began giving the shots to children in their own countries.
The government is concerned about the spread of the more contagious Delta variant by travellers and is committed to having a largely vaccinated public ahead of the Beijing Winter Olympics in February (pictured: Beijing vaccination hub)
Cambodia uses both Sinovac and Sinopharm’s shots in children aged six to 11, while regulators in Chile recently approved Sinovac for children as young as six.
In Argentina, regulators approved the Sinopharm vaccine for children as young as three.
Many developing countries left out of the race to get shots from Western pharmaceutical companies such as Pfizer and Moderna bought Chinese vaccines.
China has shipped more than 1.2 billion doses as of September, according to its Ministry of Foreign Affairs.
Even with widespread domestic and global use, not every parent is reassured about the vaccine, citing less publicly available data on the shots.
Wang Lu, who lives in the southern city of Fuzhou in Fujian province, said she is not particularly rushing to get her three-year-old son vaccinated.
‘I’m just not very clear on the vaccine’s safety profile, so I don’t really want to get him vaccinated, at the very least, I don’t want to be the first,’ Ms Wang said.
Sinovac started an efficacy trial with 14,000 child participants across multiple countries in September.
Its approval in China was based on smaller phase 1 and phase 2 trials.
Sinopharm’s Beijing shot was also approved based on smaller phase 1 and phase 2 trials.
These were published later in peer-reviewed journals.
Other parents said they were not concerned, given that many other people had already had the shot.
Wu Cong, the mother of a seven-year old, said her daughter’s school in Shanghai had not yet notified them of any vaccinations.
‘I think this isn’t too different from the flu vaccine, there’s already been so many people vaccinated, so I don’t have too many worries,’ said Ms Wu.